Testing a new drug combo before surgery for EGFR+ lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding SYS6010 to osimertinib before surgery works better than osimertinib alone for people with a type of lung cancer that has an EGFR mutation. The goal is to shrink the tumor and improve surgery outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-squamous non-small cell lung cancer (a common type of lung cancer) that is stage II to IIIB and can be removed with surgery.
- Your tumor has a specific change called an EGFR mutation (either exon 19 deletion or L858R), as shown by a lab test.
- You are between 18 and 75 years old.
- You have not received any previous cancer treatment like chemotherapy, targeted therapy, or immunotherapy.
- You are healthy enough for surgery and have a performance status of 0 or 1 (fully active or only slightly limited).
- You are willing to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
This trial tests if removing the main lung tumor followed by the targeted therapy osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer. It is for those who have not had prior treatment and are healthy enough for surgery.
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
This trial tests a combination of two drugs (BL-B01D1 and osimertinib) given before surgery to shrink EGFR-mutated lung tumors. The goal is to help make surgery more successful and improve outcomes for patients with this type of non-small cell lung cancer.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.